danicopan: Clinical Trials

8 trials of danicopan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 terminated. 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 28Completed 6, Terminated 2

Follow danicopan: new trials by email Literature Review of danicopan trials Research Report on danicopan

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Danicopan, Placebo - Geographic Atrophy
Phase 2TerminatedAlexion Pharmaceuticals, Inc.3652021-08-232025-09-05
ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19
Danicopan, Placebo, Remdesivir - COVID-19
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2012021-08-032023-06-08
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy
Phase 2TerminatedAlexion Pharmaceuticals, Inc.222018-06-202023-08-21
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
Danicopan, Placebo - C3 Glomerulopathy, C3 Glomerulonephritis
Phase 2CompletedAlexion Pharmaceuticals, Inc.132018-06-122022-10-14
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
Danicopan, Eculizumab - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2CompletedAlexion Pharmaceuticals, Inc.122018-05-082023-12-12
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
Danicopan - C3 Glomerulonephritis, Dense Deposit Disease
Phase 2CompletedAlexion Pharmaceuticals, Inc.62017-08-092021-11-04
A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
ACH-0144471 - Paroxysmal Nocturnal Hemoglobinuria
Phase 2CompletedAlexion Pharmaceuticals, Inc.82017-06-222023-03-14
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Danicopan - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2CompletedAlexion Pharmaceuticals, Inc.102017-03-312022-06-23

Conditions studied

Glomerulonephritis, Membranoproliferative (3)  ·  Hemoglobinuria, Paroxysmal (3)  ·  Hemoglobinuria (2)  ·  COVID-19 (1)  ·  Geographic Atrophy (1)

Sponsors

Alexion Pharmaceuticals, Inc. (7)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

Italy (5)  ·  United States (5)  ·  United Kingdom (4)  ·  Australia (3)  ·  South Korea (3)  ·  Belgium (2)  ·  Netherlands (2)  ·  New Zealand (2)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Japan (1)  ·  Latvia (1)  ·  Slovakia (1)

Results publications

PMID 36423588, PMID 33121236, PMID 34314483, PMID 37314061, PMID 41124654

NIH funding

2016 (3), 2017 (3)